London Publications

Research Publications Genetics


Lopez CM, Yu PY, Zhang X, Yilmaz AS, London CA, Fenger JM 2018. MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13: e0190086. Abstract in PubMed

Bandyopadhyay A, Favours E, Phelps DA, Pozo VD, Ghilu S, Kurmashev D, Michalek J, Trevino A, Guttridge D, London C, Hirotani K, Zhang L, Kurmasheva RT, Houghton PJ. 2017. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer Epub ahead of print. Abstract in PubMed

Schuh EM, Portela R, Gardner HL, Schoen C, London CA. 2017. Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res. 13: 294.  Abstract in PubMed

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. 2017. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One 12: e0181885. Abstract in PubMed

Hettlich BF, Cook L, London C, Fosgate GT. 2017. Comparison of harmonic blade versus traditional approach in canine patients undergoing spinal decompressive surgery for naturally occurring thoracolumbar disk extrusion. PLoS One 12: e0172822. Abstract in PubMed

Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC. 2017. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. BMC Cancer 17: 67. Abstract in PubMed

London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. 2017. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clin Cancer Res 23: 2565-2574. Abstract in PubMed

Lundberg AP, Francis JM, Pajak M, Parkinson EI, Wycislo KL, Rosol TJ, Brown ME, London CA, Dirikolu L, Hergenrother PJ, Fan TM. 2016. Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. Invest New Drugs. 35: 134-144. Abstract in PubMed

Rippy SB, Gardner HL, Nguyen SM, Warry EE, Portela RA, Drost WT, Hostnik ET, Green EM, Chew DJ, Peng J, London CA. 2016. A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. BMC Vet Res. 12: 257. Abstract in PubMed

Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI, Modiano JF, Kisseberth WC, London CA. 2016. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. BNC Cancer 16:784. Abstract in PubMed

Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC. 2016. Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell Non-Hodgkin lymphoma. PLoS One 11: e0159607. Abstract in PubMed

Cam M, Gardner HL, Roberts RD, Fenger JM, Guttridge DC, London CA, Cam H. 2016. ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma. Oncotarget 7: 48533-48546. Abstract in PubMed

Bid HK, Phelps DA, Xaio L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ. 2016. The bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma. Mol Cancer Ther. 15: 1018-1028. Abstract in PubMed

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C. 2016. Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.  Sci Transl Med. 8: 324.Abstract in PubMed

Arendt ML, Melin M, Tonomura N, Koltookian M, Courtay-Cahen C, Flindall N, Bass J, Boerkamp K, Megquir K, Youell L, Murphy S, McCarthy C, London C, Rutteman GR, Starkey M, Lindblad-Toh K. 2015. Genome-wide association study of Golden Retrievers identifies germ-line risk factors predisposing to mast cell tumours. PLoS Genet. 11: e1005647.  Abstract in PubMed

Gardner HL, Fenger JM, London CA 2015. Dogs as a model for Cancer. Annu Rev Anim Biosci. 4: 199-222. Abstract in PubMed

Brown ME, Bear MD, Rosol TJ, Premanandan C, Kisseberth WC, London CA. 2015. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Vet Res. 11: 206. Abstract in PubMed

Clemente-Vicario F, Alvarez CE, Rowell JL, Roy S, London CA, Kisseberth WC, Lorch G. 2015. Human genetic relevance and potent antitumor activity of heat shock protein 90 inhibition in canine lung adenocarcinoma cell lines. PLoS One 11: e0142007. Abstract in PubMed

Karrasch NM, Lerche P, Aarnes TK, Gardner HL, London CA. 2015. The effects of preoperative oral administration of carprofen or tramadol on postoperative analgesia in dogs undergoing cutaneous tumor removal. Can Vet J. 56: 817-822. Abstract in PubMed

Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD. 2015. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet Res. 11: 131. Abstract in PubMed

London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G. 2015. Impact of Toceranib/Piroxicam/Cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: A multi-institutional study. PLoS One 10: e0124889. Abstract in PubMed

Apply to the Sackler School


The priority application deadlines are as follows:

December 1: Basic Science Division PhD Programs

February 15: Building Diversity in Biomedical Sciences

March 31: Post-Baccalaureate Research Program

May 1: Clinical & Translational Science, MS in Pharmacology & Drug Development

June 15: Online Certificate in Fundamentals of Clinical Care Research